Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

0.9401 +0.0601 (+6.83%)
Delayed Quote Updated: 12:24 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
Selected for oral presentation at Clinical Trials Mini Symposium 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Update on BEACON-IPF
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.